A Review of New Findings in Adult T-cell Leukemia–Lymphoma: A Focus on Current and Emerging Treatment Strategies

Olivier Hermine, Juan Carlos Ramos, Kensei Tobinai

Research output: Contribution to journalReview article

23 Scopus citations

Abstract

Adult T-cell leukemia–lymphoma (ATL), a rare and aggressive T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1), is associated with a poor prognosis. Evidence-based standard treatment options are lacking and outcomes are generally unsatisfactory, particularly for patients with relapsed or refractory disease. Continued research is contributing to changing treatment landscape as a number of existing and investigational agents are evaluated. We describe the epidemiology of HTLV-1 and ATL, discuss the biology behind the disease, review current treatment practices and guidelines, and provide an overview of emerging therapies in ATL, with a focus on those for relapsed or refractory disease.

Original languageEnglish (US)
Pages (from-to)135-152
Number of pages18
JournalAdvances in Therapy
Volume35
Issue number2
DOIs
StatePublished - Feb 1 2018

Keywords

  • Adult T-cell leukemia–lymphoma
  • Chemotherapy
  • Human T-cell lymphotropic virus type 1
  • Oncology
  • Relapsed/refractory disease
  • Targeted agents

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A Review of New Findings in Adult T-cell Leukemia–Lymphoma: A Focus on Current and Emerging Treatment Strategies'. Together they form a unique fingerprint.

  • Cite this